- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00120471
Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies
A Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and Their Infants
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Rates of MTCT of HIV have dramatically decreased in resource-rich countries since the introduction of antiretroviral (ARV) prophylaxis; increased prenatal care, HIV testing, and counseling; elective cesarean delivery; and avoidance of breastfeeding. In resource-limited countries, however, MTCT of HIV continues to be a widespread problem. In these parts of the world, ARV prophylaxis is too expensive and too difficult to adequately administer; mothers often do not receive proper prenatal care; cesarean delivery may pose risks to the mother and and her infant; and due to the lack of safe, affordable, and socially acceptable alternatives, HIV infected mothers breastfeed their infants. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of TDF in HIV infected pregnant women and their infants.
Participants in this study will be enrolled through 12 months after delivery. During the last trimester of pregnancy, HIV infected women will be screened for eligibility. Women will be enrolled into the study upon presentation at the study site for delivery. Standard of care with ARVs for prevention of MTCT will be offered to all women and their infants both inside and outside of the study; however, such ARVs will not be provided by this study.
There will be four cohorts in this study:
- Cohort 1 women will receive a single dose of TDF (SD TDF) during active labor. Cohort 1 women will be hospitalized at the delivery facility through Day 3 postpartum.
- Cohort 2 women will not receive any TDF. Cohort 2 women will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.
- Cohort 3 will not begin enrolling women until data safety evaluations of Cohorts 1 and 2 are completed. Cohort 3 women will be hospitalized at the delivery facility through Day 7 postpartum. Women in Cohort 3 will receive SD TDF during active labor, and their infants will receive TDF at birth and on Days 3 and 5 after birth.
- Cohort 4, which was added to the study based on a review of data from the other cohorts, will be similar to Cohort 3, except that infants will receive daily TDF for the 7 days after birth. Researchers believe this higher and more frequent dosing of TDF in infants will help them meet the target TDF concentration specified in the protocol.
There will be seven study visits for women at study entry (Day 0), Day 2, between Days 5 and 7, at Weeks 6 and 12, and at Months 6 and 12 postpartum. Medical history, a short physical exam, and blood collection will occur at all visits. In Cohorts 1, 3, and 4, blood collection for PK studies will occur prior to receiving TDF and seven times post-dose.
There will be eight study visits for infants, which will occur within 24 hours of birth; on Day 3; between Days 5 and 7; at Weeks 6 and 12; and at Months 6, 9, and 12. Medical history, a physical exam, and blood collection will occur at all visits. Infants will have x-rays to assess bone health at Day 3 and Month 3, except in Cohort 4, which will not include x-rays of infants. Infants of Cohort 1 will have blood collection for PK studies at birth and four times after birth. Infants of Cohorts 2 and 3 will undergo blood collections for PK studies at birth, Day 3, and Day 5. Blood collection at these visits will occur before receiving TDF and 2 and 10 hours after receiving TDF. At birth, an additional collection will occur 18 to 24 hours after receiving TDF, and on Day 5, two additional collections will occur--at 18 to 24 hours and at 36 to 48 hours after receiving TDF. Infants of Cohort 4 will have blood collection for PK studies at birth and after their fourth and seventh doses of TDF.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Rio de Janeiro, Brasilien, 20221-903
- HSE-Hospital dos Servidores do Estado CRS
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien
- Federal Univ. of Minas Gerais
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasilien, 91350-200
- Hospital Nossa Senhora da Conceicao CRS
-
Porto Alegre, Rio Grande Do Sul, Brasilien
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
-
-
-
-
Blantyre, Malawi
- College of Med. JHU CRS
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria for HIV Infected Pregnant Women:
- HIV-1 infected
- Intend to deliver at the study site
- Willing to be contacted or visited at home
- Willing to be admitted to and remain in the delivery facility through Day 3 postpartum (Cohort 1) or Day 7 postpartum (Cohorts 2 and 3)
Exclusion Criteria for HIV Infected Pregnant Women:
- Prior treatment with TDF
- Active opportunistic infection
- Serious bacterial infection
- Chronic malabsorption or diarrhea during the current pregnancy
- Clinically significant disease or condition that, in the opinion of the study clinician, would interfere with the study
- Known multiple gestation (twins, etc.) prior to study entry
- Participation in any other therapeutic or vaccine trial during the current pregnancy
- Use of certain medications
- Any other condition or situation that, in the opinion of the investigator, would interfere with the study
- For Cohort 4, use of atazanavir or lopinavir/ritonavir (Kaletra) within 2 weeks of anticipated delivery
Exclusion Criteria for Infants Born to HIV Infected Pregnant Women:
- Birth weight of less than 2 kg (4.4 lbs)
- Severe congenital malformation or other medical condition that may affect survival and, in the opinion of the clinician, participation in this study
- Grade 2 or higher serum creatinine level or any other Grade 3 or higher toxicity
- Part of a multiple birth (twins, etc.)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: 1
Pregnant participants will receive a single dose of TDF during active labor.
These participants will be hospitalized at the delivery facility through Day 3 postpartum.
|
600-mg tablet taken orally once daily
Andre navne:
4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
Andre navne:
6-mg/kg oral suspension taken at birth and daily for 7 days after birth
Andre navne:
|
Eksperimentel: 2
Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum.
Their infants will receive TDF at birth and on Days 3 and 5 after birth.
|
600-mg tablet taken orally once daily
Andre navne:
4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
Andre navne:
6-mg/kg oral suspension taken at birth and daily for 7 days after birth
Andre navne:
|
Eksperimentel: 3
Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum.
They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.
|
600-mg tablet taken orally once daily
Andre navne:
4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
Andre navne:
6-mg/kg oral suspension taken at birth and daily for 7 days after birth
Andre navne:
|
Eksperimentel: 4
Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum.
Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.
|
600-mg tablet taken orally once daily
Andre navne:
4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
Andre navne:
6-mg/kg oral suspension taken at birth and daily for 7 days after birth
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Frequency of adverse events with a severity of Grade 3 or higher attributable to receipt of TDF
Tidsramme: Throughout study
|
Throughout study
|
Maintenance of infant serum concentrations of TDF greater than 50 ng/ml
Tidsramme: Through Week 1
|
Through Week 1
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Maternal HIV-1 RNA levels
Tidsramme: At study entry, Days 5 to 7, and Week 6
|
At study entry, Days 5 to 7, and Week 6
|
Viral resistance to TDF in all HIV-1 infected infants, all of the corresponding mothers (transmitters), and a subset of mothers whose infants are not infected (nontransmitters). Analysis of TDF in mothers may include testing of breastmilk samples.
Tidsramme: Throughout study
|
Throughout study
|
HIV infection in infants
Tidsramme: Throughout study
|
Throughout study
|
TDF concentration in amniotic fluid and breast milk
Tidsramme: Through Week 1
|
Through Week 1
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: Mark Mirochnick, MD, Boston Medical Center
- Studiestol: Taha Taha, MD, PhD, Johns Hopkins University
- Studiestol: Regis Kreitchmann, MD, Centro Municipal de DST/AIDS, Irmandade Santa Casa de Misericordia de Porto Alegre
Publikationer og nyttige links
Generelle publikationer
- Abrams EJ. Prevention of mother-to-child transmission of HIV--successes, controversies and critical questions. AIDS Rev. 2004 Jul-Sep;6(3):131-43.
- Capparelli E, Rakhmanina N, Mirochnick M. Pharmacotherapy of perinatal HIV. Semin Fetal Neonatal Med. 2005 Apr;10(2):161-75. doi: 10.1016/j.siny.2004.10.001. Epub 2005 Jan 20.
- Thorne C, Newell ML. Mother-to-child transmission of HIV infection and its prevention. Curr HIV Res. 2003 Oct;1(4):447-62. doi: 10.2174/1570162033485140.
- Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, Baker CJ. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol. 2003 Feb;43(2):133-40. doi: 10.1177/0091270002239821.
- Osorio LE, Boechat MI, Mirochnick M, Kumwenda N, Kreitchmann R, Emel L, Pinto J, Joao E, Santos B, Swenson M, George K, Sato P, Mofenson L, Nielsen-Saines K; HIV Prevention Trials Network (HPTN) 057 Protocol Team. Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. Pediatr Infect Dis J. 2017 Feb;36(2):184-188. doi: 10.1097/INF.0000000000001386.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- HIV-infektioner
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Reverse transkriptasehæmmere
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Anti-HIV-midler
- Anti-retrovirale midler
- Tenofovir
Andre undersøgelses-id-numre
- HPTN 057
- 10143 (Registry Identifier: DAIDS-ES)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV-infektioner
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
Institut PasteurRekruttering
-
Universidad del DesarrolloAfsluttetHealthcare Associated InfectionChile
-
The University of Texas Health Science Center,...EurofinsAfsluttetOdontogen Deep Space Neck InfectionForenede Stater
-
Imelda Hospital, BonheidenAfsluttetHealthcare Associated InfectionBelgien
-
Centre Hospitalier Universitaire de NīmesRekrutteringÆldre | Healthcare Associated InfectionFrankrig
-
Centre Hospitalier Universitaire, AmiensAfsluttetHealthcare Associated Infection | IglerFrankrig
-
University of PennsylvaniaAfsluttetAntimikrobiel resistensForenede Stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentAfsluttetMenneskelig mikrobiomForenede Stater
-
Universidad Autonoma de Nuevo LeonUkendtSundhedsrelaterede infektioner
Kliniske forsøg med Tenofovir disoproxil fumarate
-
ANRS, Emerging Infectious DiseasesIkke rekrutterer endnuHepatitis B-virus - kronisk aktiv
-
University of Colorado, DenverAfsluttetSunde frivillige | Farmakokinetik
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RekrutteringDekompenseret hjertesvigtForenede Stater
-
Technical University of MunichGilead Sciences; MUC Research GmbHAfsluttet
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetSund og raskForenede Stater
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID)AfsluttetSund og rask | HIVForenede Stater
-
Guy's and St Thomas' NHS Foundation TrustGilead Sciences; ViiV HealthcareAfsluttetHIV-1-infektionDet Forenede Kongerige
-
Nucorion Pharmaceuticals, Inc.Ligand PharmaceuticalsAfsluttetKronisk hepatitis BForenede Stater
-
Merck Sharp & Dohme LLCAktiv, ikke rekrutterendeProfylakse | Humant immundefektvirus type 1 | HIV-IForenede Stater, Sydafrika, Uganda
-
Samjin Pharmaceutical Co., Ltd.Afsluttet